Exenatide extended-release pre-filled pen (Bydureon® BCise®): a profile of its use
- 68 Downloads
The Bydureon® BCise® pre-filled pen was developed largely to simplify self-administration of exenatide extended-release for patients with type 2 diabetes, being comfortable and intuitive to use, with easy-to-mix medication, sterile and safe needle containment, reliable/accurate dose delivery, and indicators of complete dose delivery and device use. Subcutaneous self-injection with Bydureon BCise involves three simple key steps (mixing, unlocking and pressing against the skin to inject) and has a needle that remains hidden, ensuring sterility and reducing the likelihood of accidental injury. In a single-injection study, the Bydureon BCise pre-filled pen was largely considered ‘easy’/‘very easy’ to use, and had a high rate of successful injection completion, including among lay users with dexterity or visual impairment. As an add-on to diet and exercise or oral glucose-lowering therapy, Bydureon BCise once weekly improved glycaemic control and provided glycaemic benefits over subcutaneous twice-daily exenatide and oral once-daily sitagliptin. Bydureon BCise was also generally well tolerated and appeared to have a better gastrointestinal profile, but more injection-site reactions, than twice-daily exenatide, and a less favourable gastrointestinal profile, but greater patient satisfaction, than sitagliptin.
The manuscript was reviewed by: S. Chinwong, Department of Pharmaceutical Care, Chiang Mai University, Chiang Mai, Thailand; A.D. Mooradian, Department of Medicine, University of Florida College of Medicine, Jacksonville, FL, USA; W.M. Valencia, Geriatric Research, Education and Clinical Center (GRECC), Miami VA Healthcare System, Miami, FL. USA. During the peer review process, AstraZeneca, the marketing-authorization holder of Bydureon® BCise®, was offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflict of interest
E. D. Deeks is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.
- 7.International Diabetes Federation. IDF clinical practice recommendations for managing type 2 diabetes in primary care. Brussels: International Diabetes Federation; 2017.Google Scholar
- 11.Byetta (exenatide) solution for injection in prefilled-pen: summary of product characteristics (EU).Södertälje (Sweden): AstraZeneca AB; 2018.Google Scholar
- 12.Byetta (exenatide) injection : US prescribing information. Wilmington (DE): AstraZeneca Phamaceuticals LP; 2015.Google Scholar
- 13.Bydureon 2 mg powder and solvent for prolonged-release suspension for injection. Bydureon summary of product characteristics (EU). Södertälje (Sweden): AstraZeneca AB; 2018. p. 2–20.Google Scholar
- 14.Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen. Bydureon summary of product characteristics (EU). Södertälje (Sweden): AstraZeneca AB; 2018. p. 21–39.Google Scholar
- 15.Bydureon® (exenatide extended-release) for injectable suspension, for subcutaneous use: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2018.Google Scholar
- 17.American Diabetes Association. Introduction: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S1–2.Google Scholar
- 23.Bydureon® BCise™ (exenatide extended-release) injectable suspension, for subcutaneous use : US prescribing information. Wilmington (DE): AstraZeneca Phamaceuticals LP; 2017.Google Scholar
- 24.Bydureon 2 mg prolonged-release suspension for injection in pre-filled pen (BCise). Bydureon summary of product characteristics (EU). Södertälje (Sweden): AstraZeneca AB; 2018. p. 40–59.Google Scholar